Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a leader in the development of differentiated targeted radiotherapies, announced today that new preclinical data for ...
Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today is providing a number of strategic updates, including its recently executed option agreement with Incyte ...
Purespring co-author paper with real world evidence on epidemiological prevalence data of NPHS2 pathogenic variants across global populations London – 4 November 2025 – Purespring Therapeutics, a ...
21m
Costamare Inc. Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2025
MONACO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Costamare Inc. (“Costamare” or the “Company”) (NYSE: CMRE) today reported unaudited financial results for the third quarter and nine-month period ended ...
Record Q3 Revenue of $150.8 Million, up 63% Y/Y Driven by Accelerating MTM Growth and Record ARPU Record Q3 ExtraCash Monetization Rate Net of Losses of 4.8%, up 45bps Y/Y as Originations Grew 49% to ...
Returned $746 million to shareholders year to date through share repurchases and dividends ...
UL Solutions Inc. , a global safety science leader in independent third-party testing, inspection and certification services and related software and advisory offerings, today reported results for the ...
Solid momentum across all segments, tracking well to 2025 outlook Third quarter and year to date operating highlights: Three months ...
Silicon Labs , the leading innovator in low-power wireless, reported financial results for the third quarter, which ended October 4, ...
Xometry’s fourth quarter 2025 and full year 2025 financial outlook is based on a number of assumptions that are subject to change and may be outside of its control. If actual results vary from these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback